Generics Industry Faces Five Major Challenges, Actavis CEO Says (We're Partly Responsible For One Of Them, He Acknowledges)
Executive Summary
U.S. ANDA makers are ending their silver anniversary year on a glum note
You may also be interested in...
ANDA Filing Free-For-All? Matrix's Stay In Kaletra Case Could Remove Risks Of Submitting Early Dual Certification Generic Drug Applications
Matrix's ability to win a stay of litigation over Kaletra patents - and thus avoid a potential forfeit of its generic exclusivity - suggests a possible strategy for other early ANDA filers
Ranbaxy Transfers Atorvastatin, Tamsulosin Filings To Ohm Labs While Valacyclovir Rakes Big Gains
MUMBAI - Ranbaxy - the Indian affiliate of Daiichi Sankyo - is believed to have transferred its abbreviated new drug application filing for Lipitor to its New Jersey-based Ohm Labs facility, after U.S. FDA imposed import restrictions last summer on two of its biggest manufactuirng facilities in India
Pediatric Exclusivity For Brand Biologics Added In Senate FOB Provision, But Generics Have $1 Bil. In Leverage From CBO Score
The roll-out of the health care reform bill now under debate in the Senate is a good news/bad news event for the generic industry